Stockreport

Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meetin...

Atara Biotherapeutics, Inc.  (ATRA) 
Last atara biotherapeutics, inc. earnings: 2/27 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: investors.atarabio.com/investor-relations
PDF ATA3219 Demonstrates Complete CD19-Specific B-Cell Depletion Against Systemic Lupus Erythematosus and Multiple Sclerosis Patient Peripheral Blood Mononuclear CellsATA321 [Read more]